Teva Pharmaceutical Industries (TEVA) Attains FDA's Fast Track Designation for Emrusolmin

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best drug stocks to buy right now. Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced on September 9 that it attained Fast Track designation from the U.S. Food and Drug Administration for emrusolmin, which is an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development.

Management reported that there is an urgent need for new therapeutic options targeting MSA, a devastating and rare neurodegenerative disorder, because of the absence of treatments available that affect disease progression.

Part of a strategic collaboration with MODAG GmbH, a privately held German biotech company, emrusolmin is in the process of being evaluated in a Phase 2 trial to assess its efficacy and safety. Emrusolmin is a small molecule targeting the alpha synuclein protein, believed to be pivotally involved in the pathogenesis of MSA.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) added that the U.S. FDA granted Orphan Drug designation to emrusolmin for MSA in 2022.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, produces, and sells medicines. Its operations are divided into the US, Europe, and International Markets geographical segments.

Each business segment covers the entire product portfolio in that region, including specialty, generics, and over-the-counter (OTC) products.

While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.